ReviewEuropean heart journal open2026

Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.

Jose Seijas-Amigo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.